跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
歐 聰億
助理教授
,
感染科
主治醫師
,
臺北市立萬芳醫院
https://orcid.org/0000-0001-9093-1615
電子郵件
93023
w.tmu.edu
tw
h-index
872
引文
17
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2026
每年研究成果
概覽
指紋
網路
研究成果
(71)
類似的個人檔案
(6)
指紋
查看啟用 Tsong Yih Ou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Immunology and Microbiology
Infectious Disease
100%
Infection
100%
Candida Albicans
19%
Vancomycin-Resistant Enterococcus
19%
COVID-19
19%
Urinary Tract
17%
Mortality Rate
16%
Infectious Agent
15%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Glucose
12%
Escherichia coli
10%
Normal Human
9%
Immunogenicity
9%
Elizabethkingia Meningoseptica
9%
Immunology and Microbiology
9%
Necrotizing Fasciitis
9%
Ropeginterferon Alpha2b
9%
Vibrio Cholerae
9%
Hospital Mortality
9%
Hemodialysis
9%
Hepatitis C
9%
Enterococcus faecium
9%
Influenza A Virus (H7N9)
9%
Achromobacter Xylosoxidans
9%
Cryptococcus neoformans
9%
Rhodotorula
9%
Trichosporon
9%
Influenza Vaccine
9%
Hemagglutinin
9%
Single-Chain Variable Fragment
9%
Chromosome Loss
9%
Hepatitis B Virus
9%
Omicron Coronavirus Variant
9%
Delftia acidovorans
9%
Homozygosity
9%
Cell Culture
9%
Tocilizumab
9%
Emerging Pathogen
9%
Bacterium
8%
Antigen
6%
Homozygote
6%
Pseudomonas
6%
Gram-Negative Bacteria
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
45%
Pneumonia
32%
Acinetobacter Baumannii
31%
Bloodstream Infection
31%
Colistimethate
25%
Tigecycline
23%
Infectious Agent
21%
Lemierre's Syndrome
19%
Mortality Rate
18%
Combination Therapy
15%
Urinary Tract Infection
13%
Steroids
12%
Sepsis
10%
Respiratory Tract
10%
Clinical Trial
9%
Hospital Infection
9%
Cerebrovascular Accident
9%
Klebsiella pneumoniae
9%
Chryseobacterium indologenes
9%
Elizabethkingia Meningoseptica
9%
Healthcare Associated Infection
9%
Ecological Study
9%
Delftia acidovorans
9%
Therapy Resistance
9%
Hepatitis C
9%
Hepatitis B Virus
9%
Chronic Liver Disease
9%
Randomized Controlled Trial
9%
Ropeginterferon Alpha2b
9%
Meropenem
9%
Penicillinase
9%
Brain Abscess
9%
Antibiotic Resistance
9%
Acute Heart Infarction
9%
Fosfomycin
9%
Hyperbilirubinemia
9%
Emphysematous Cholecystitis
9%
Bacterium
9%
Antiinfective Agent
6%
Hepatitis C Virus
6%
Antibiotics
6%
Antimicrobial Agent
5%
Hospital Mortality
5%
SARS Coronavirus
5%
Medicine and Dentistry
Infection
31%
Sepsis
23%
Bloodstream Infection
19%
COVID-19
19%
Cohort Analysis
19%
Mortality Rate
16%
Escherichia coli
13%
Urinary Tract Infection
13%
Pneumonia
11%
Pathogen
11%
Patient with Diabetes
11%
Hemodialysis
11%
Apoplexy
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Glucose
9%
Chronic Liver Disease
9%
Hepatitis B Virus
9%
Hepatitis C
9%
Intensive Care Unit
9%
Hospital Mortality
9%
Omicron Coronavirus Variant
9%
Malaria Falciparum
9%
Disinfectant Agent
9%
Tocilizumab
9%
Pneumocystis Jirovecii
9%
Caspofungin
9%
Hyperbilirubinemia
9%
Lemierre's Syndrome
9%
Ventricular Septal Defect
9%
Weil's Disease
9%
Plasma Exchange
9%
Necrotizing Fasciitis
9%
Pregnant Woman
9%
Thigh
9%
Malaria
9%
Endocarditis
9%
Stress Hyperglycemia
9%
Aseptic Meningitis
9%
Salvage Therapy
9%
Acute Heart Infarction
9%
Ecological Study
9%
Myocardial Infarction
9%
Pulmonary Valve
9%
Urinary Catheterization
9%
Ritonavir
9%
Nirmatrelvir
9%
Urinary System
9%
Steroid
9%
Immunology
9%
Glycemic
7%
